Table 1.
Clinicopathological characteristics baseline in relation to AQP9 expression level in FUSCC cohort
| Characteristics | FUSCC cohort (N = 380) |
AQP9 expression | χ2 | p | |
|---|---|---|---|---|---|
| High (N = 190) |
Low (N = 190) |
||||
| N (%) | |||||
| Age | 0.296 | 0.587 | |||
| < 60 years | 253 (66.6) | 124 (65.3) | 129 (67.9) | ||
| ≥ 60 years | 127 (33.4) | 66 (34.7) | 61 (32.1) | ||
| Gender | 0.435 | 0.510 | |||
| Male | 258 (67.9) | 132 (69.5) | 126 (66.3) | ||
| Female | 122 (32.1) | 58 (30.5) | 64 (33.7) | ||
| BMI | 0.541 | 0.462 | |||
| < 25 kg/m2 | 231 (60.8) | 112 (58.9) | 119 (62.6) | ||
| ≥ 25 kg/m2 | 149 (39.2) | 78 (41.1) | 71 (37.4) | ||
| pT stage | 34.336 | < 0.001 | |||
| T1–T2 | 307 (80.8) | 131 (68.9) | 176 (92.6) | ||
| T3–T4 | 73 (19.2) | 59 (31.1) | 14 (7.4) | ||
| pN stage | 14.246 | < 0.001 | |||
| N0 | 334 (87.9) | 155 (81.6) | 179 (94.2) | ||
| N1 | 46 (12.1) | 35 (18.4) | 11 (5.8) | ||
| pM stage | 40.347 | < 0.001 | |||
| M0 | 310 (81.6) | 131 (68.9) | 179 (94.2) | ||
| M1 | 70 (18.4) | 59 (31.1) | 11 (5.8) | ||
| AJCC stagea | 34.072 | < 0.001 | |||
| I–II | 292 (76.8) | 122 (64.2) | 170 (89.5) | ||
| III–IV | 88 (23.2) | 68 (35.8) | 20 (10.5) | ||
| ISUP grade | 4.218 | 0.040 | |||
| G1–G2 | 182 (47.9) | 81 (42.6) | 101 (53.2) | ||
| G3–G4 | 198 (52.1) | 109 (57.4) | 89 (46.8) | ||
FUSCC Fudan University Shanghai Cancer Center, BMI body mass index
aThe AJCC staging system is a classification system developed by the American Joint Committee on Cancer for describing the extent of disease progression in cancer patients. It utilizes in part the TNM scoring system: Tumor size, Lymph Nodes affected, Metastases